C6-h12-o6 anti-clotting factors in vampire bat saliva may save your life. gas appliance manufacturers association

To understand why bats have this protein in their saliva and why it may be medically useful, we first need to understand how clots form. Whenever a blood vessel is damaged, collagen fibers are exposed under the severed lining of the vessel. Platelets, one of the several blood cell types, will begin to stick to the collagen fibers and to one another until the damaged area is covered. This creates a platelet "plug" that stops immediate blood loss. Once the platelet plug is in place, a cascade of clotting factors (a vital one being a chemical called fibrin) will build a clot "seal" over the platelet plug that forms a more permanent barrier to blood loss while the vessel heals.

After the vessel heals and the clot is no longer needed, a chemical called plasminogen is activated and becomes plasmin. Plasmin then breaks down the clot by solubilizing fibrin. This is a safe way to get rid of the clot so that it doesn’t come off in one piece and then lodge itself into a small vessel where it can cut off circulation to parts of the body. However, sometimes clots are not broken down properly and can cut off blood flow to the brain (stroke) or heart (heart attack). When this happens, we need to manually turn plasminogen into plasmin using plasminogen activators, so that plasmin can break down the clot and restore blood flow.

The plasminogen activators in vampire bat saliva were first described by Dr. Christine Hawkey in a letter to Nature in the 1960s. In addition to plasminogen activators, Hawkey later went on to describe platelet aggregation inhibitors in vampire bat saliva as well. Vampire bats do not suck blood directly as mosquitoes do; instead they puncture the skin with their teeth and lap the blood with their tongues as it seeps through the wound. This strategy requires the inhibition of platelet plugs and clots which would stop the blood from continuing to flow during the bat’s meal.

Desmoteplase, which is derived from the plasminogen activators in vampire bat saliva originally described by Hawkey, seems to have some advantages over currently used plasminogen activators (which are often based on chemicals in humans). Current drugs are only approved for use up to 3 hours after symptom onset, and Dr. Michel Torbey at OSU MC is hopeful that desmoteplase will demonstrate efficacy up to 9 hours after symptom onset, which could drastically reduce the number of deaths. From the press release:

"Prompt medical care within three hours is very important for recovery from a stroke, but attempts to find drugs that extend the treatment window have not been successful," added Torbey. "If the study findings back up our hopes and expectations, desmoteplase could be a real game changer in our ability to help patients."

In addition to expanding the treatment window, desmoteplase is more potent and specific than current drugs. One current plasminogen activator is even linked to neurotoxicity in some patients, so there is high demand for newer and better drugs to treat problematic clots. If approved, this drug could reduce the risk of death in stroke patients who live in remote areas and may not be able to make it to the emergency room within the three hour window.